An amino-acid switch in the BCR-ABL kinase domain modifies sensitivity to imatinib mesylate

被引：0
|
作者：
T Leguay
V Desplat
V Lagarde
G Marit
J Reiffers
F-X Mahon
机构：
[1] Laboratoire hématopoïèse leucémique et cible thérapeutique INSERM E0217,
[2] Université Victor Segalen Bordeaux II,undefined
[3] Service des Maladies du Sang,undefined
[4] Hôpital du Haut-Lévèque,undefined
来源：
Leukemia | 2005年 / 19卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：1671 / 1673
页数：2
相关论文
共 50 条
  • [1] An amino-acid switch in the BCR-ABL kinase domain modifies sensitivity to imatinib mesylate
    Leguay, T
    Desplat, V
    Lagarde, V
    Marit, G
    Reiffers, J
    Mahon, FX
    LEUKEMIA, 2005, 19 (09) : 1671 - 1673
  • [2] AN INSERTION IN THE BCR-ABL KINASE DOMAIN CONTRIBUTES TO IMATINIB MESYLATE RESISTANCE
    Pennisi, M. S.
    Stagno, F.
    Massimino, M.
    Stella, S.
    Di Raimondo, F.
    Messina, A.
    Vigneri, P.
    HAEMATOLOGICA, 2008, 93 : S66 - S66
  • [3] AN INSERTION IN THE BCR-ABL KINASE DOMAIN CONTRIBUTES TO IMATINIB MESYLATE RESISTANCE
    Vigneri, P.
    Stagno, F.
    Massimino, M.
    Berretta, S.
    Stella, S.
    Del Fabro, V.
    Messina, A.
    Di Raimondo, F.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2008, 93 : 312 - 313
  • [4] Phosphorylation of tyrosine 393 in the kinase domain of Bcr-Abl influences the sensitivity towards imatinib in vivo
    C Miething
    C Mugler
    R Grundler
    J Hoepfl
    R-Y Bai
    C Peschel
    J Duyster
    Leukemia, 2003, 17 : 1695 - 1699
  • [5] Phosphorylation of tyrosine 393 in the kinase domain of Bcr-Abl influences the sensitivity towards imatinib in vivo
    Miething, C
    Mugler, C
    Grundler, R
    Hoepfl, J
    Bai, RY
    Peschel, C
    Duyster, J
    LEUKEMIA, 2003, 17 (09) : 1695 - 1699
  • [6] Not all imatinib resistance in CML are BCR-ABL kinase domain mutations
    Wei, Yuan
    Hardling, Mats
    Olsson, Bob
    Hezaveh, Rahil
    Ricksten, Anne
    Stockelberg, Dick
    Wadenvik, Hans
    ANNALS OF HEMATOLOGY, 2006, 85 (12) : 841 - 847
  • [7] Not all imatinib resistance in CML are BCR-ABL kinase domain mutations
    Yuan Wei
    Mats Hardling
    Bob Olsson
    Rahil Hezaveh
    Anne Ricksten
    Dick Stockelberg
    Hans Wadenvik
    Annals of Hematology, 2006, 85 : 841 - 847
  • [8] Type of BCR-ABL transcript predicts response to imatinib mesylate.
    Sharma, P
    Kumar, L
    Kochupillai, V
    Mohanty, S
    Sharma, A
    Seth, T
    BLOOD, 2005, 106 (11) : 292B - 292B
  • [9] Imatinib mesylate, a selective inhibitor of BCR-ABL, in chronic myeloid leukemia
    Carella, Angelo Michele
    EXPERT REVIEW OF ANTICANCER THERAPY, 2007, 7 (03) : 249 - 251
  • [10] ABSENCE OF BCR-ABL KINASE DOMAIN MUTATIONS IN CHRONIC MYELOCYTIC LEUKEMIA (CML) QATARI PATIENTS ON IMATINIB MESYLATE (IM) TREATMENT
    Al-Dewik, I.
    Jewell, P.
    Elayoubi, R.
    Morsi, M.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2010, 95 : 532 - 532
12345